



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Original article

Carbapenem-resistant bacilli in a hospital in southern Brazil: prevalence and therapeutic implications



Jéssica Endy Scariot Costa ^{a,*}, Keite da Silva Nogueira ^b, Clóvis Arns da Cunha ^c

^a Universidade Federal do Paraná, Faculdade de Medicina, Curitiba, PR, Brazil

^b Universidade Federal do Paraná, Complexo Hospital de Clínicas da Universidade Federal do Paraná, Laboratório de Microbiologia, Curitiba, PR, Brazil

^c Universidade Federal do Paraná, Faculdade de Medicina, Departamento de Saúde Coletiva, Curitiba, PR, Brazil

ARTICLE INFO

Article history:

Received 21 March 2020

Accepted 13 July 2020

Available online 28 August 2020

Keywords:

MDR GNB

Susceptibility profile

Prevalence

Carbapenems

ABSTRACT

Background: Gram-negative bacilli (GNB), notably *Acinetobacter* spp., *Pseudomonas* spp., and *Klebsiella* spp., are becoming increasingly resistant to carbapenems and are associated with high health care costs and mortality, becoming a global concern.

Objective: To determine the prevalence rates of carbapenem resistance among *Acinetobacter* spp., *Pseudomonas* spp., and *Klebsiella* spp. in the main sites of nosocomial infection at a tertiary care hospital in southern Brazil and the consequent therapeutic implications.

Methods: Cultures processed at the institution's laboratory in 2017 were analyzed, and those positive for *Acinetobacter* spp., *Pseudomonas* spp., and *Klebsiella* spp. were identified. Antibiograms were evaluated for meropenem sensitivity following the Clinical Laboratory Standards Institute guidelines.

Results: *Acinetobacter* spp. had the lowest prevalence among the three GNB, and resistance of this pathogen to meropenem at different sites of infection ranged from 36% (blood) to 82% (respiratory tract). *Pseudomonas* spp. was highly prevalent at the respiratory tract (31%) and had a high resistance rate to meropenem in rectal swab samples (71%), but a relatively low frequency at infection sites (skin/soft tissue, 13%; blood, 25%). *Klebsiella* spp. was identified in 7.5% of the blood cultures and 15% of the urine cultures and was the chief colonizer among all pathogens, representing 54% of all rectal swab samples, of which 53% were meropenem resistant. At sites of infection, rates of *Klebsiella* spp. resistant to meropenem ranged from 19% (skin) to 55% (vascular catheter).

Conclusions: The prevalence of carbapenem-resistant GNB at our hospital was relatively low compared to national and international data; thus, meropenem remains a good therapeutic option against these bacteria. Other antibiotics effective against GNB, such as ceftazidime, cefepime, and piperacillin-tazobactam, can be used in most cases, while meropenem should

* Corresponding author at: Jéssica Endy Scariot Costa, Universidade Federal do Paraná, Faculdade de Medicina, 240, 1804A, Amintas de Barros, Curitiba, PR, 80060-205, Brazil.

E-mail addresses: jessica_endy@hotmail.com, jessicaendysc@gmail.com (J.E. Costa).

<https://doi.org/10.1016/j.bjid.2020.07.006>

1413-8670/© 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

be reserved for patients with sepsis. Strict contact precaution measures are still needed, given the high resistance rate observed at the colonizing site.

© 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Antimicrobial resistance is a natural process that is being exacerbated mainly by the indiscriminate use of antimicrobials¹ in the medical field (e.g., unnecessary prescriptions, incorrect administration, and over-the-counter sales²) and activities related to agriculture and livestock (use of antibiotics for animal growth).³

Infections by antimicrobial-resistant organisms are associated with increased mortality. These pathogens also curb empirical treatment of infections, raise costs associated with health care, and limit therapeutic options to agents with lower efficacy and more side effects.^{4,5} According to the World Health Organization (WHO), this scenario threatens the global public health with the prospect of a post-antibiotic era when antibiotics will lose efficacy to treat infections; this could affect all medical areas and increase global morbidity and mortality rates.⁶

Among all pathogens involved in multidrug-resistant infections, Gram-negative bacilli (GNB) – mainly *Acinetobacter* spp., *Pseudomonas* spp., and *Klebsiella* spp.^{7,8} – are the most threatening, since no new class of antibiotics has been developed against these bacteria.⁹ Additionally, the rates of resistance to carbapenems (the current drug of choice for multidrug-resistant infections) have increased mainly due to KPC, NDM, and OXA-48 carbapenemases, making the management of infections by these bacteria a concerning public health problem worldwide.⁷ Beta-lactam agents like carbapenems are especially important in the management of patients in transplant and intensive care units (ICUs), and among individuals on chemotherapy, since multidrug-resistant (MDR) GNB are a frequent cause of sepsis in these environments.¹⁰

Cases of resistance to carbapenems are managed by long-established drugs such as aminoglycosides, tigecycline, colistin, and polymyxin. In addition to the potential side effects of these medications, including hearing loss and kidney failure, resistance rates to these drugs have increased along with the emergence of pandrug-resistant (PDR) organisms.¹⁰

According to the WHO Global Action Plan, one of the measures to prevent the advance of antimicrobial resistance is the generation and sharing of epidemiological information reporting the particularities of each region.⁶ Considering the importance of this measure and the fact that Brazil is part of BRICS (which forecasts an increase in the use of antimicrobials),¹¹ this study was developed to evaluate the prevalence and profile of susceptibility to carbapenems among the GNB *Acinetobacter* spp., *Pseudomonas* spp., and *Klebsiella* spp. and the prevalence of carbapenem resistance among these GNB at a tertiary hospital in Curitiba (the eighth most populous city in Brazil, according to the Brazilian Institute of

Geography and Statistics),¹² along with addressing their consequent therapeutic implications.

Materials and methods

This was a retrospective, cross-sectional study in patients who had cultures processed during 2017 at the Clinical Analysis Laboratory Unit (ULAC) of the Clinics Hospital Complex of Federal University of Paraná (CHC-UFPR), in Curitiba, southern Brazil. The CHC-UFPR is a large tertiary care hospital with 500 hospital beds (85 of which are distributed across three ICUs: adult, pediatric, and neonatal), obstetric and surgical centers, and outpatient clinics of various specialties. The hospital is a referral center for some specialties (bone marrow transplantation, hematologic diseases, and cystic fibrosis) and offers care for patients across all ages and races, of both sexes, and with diseases with and without comorbidities.

The cultures were routinely processed in the laboratory following standard microbiology methods. Identification of the bacteria and antimicrobial susceptibility tests were performed using the automated system Vitek 2 (bioMérieux S.A., Marcy-l'Étoile, France) and interpreted according to Clinical Laboratory Standards Institute (CLSI) guidelines. Meropenem was chosen to represent the carbapenem class since it is the most frequently used antibiotic of this class.

The study included 1142 positive cultures for *Pseudomonas* spp., *Acinetobacter* spp., and *Klebsiella* spp. obtained from patients across all ages. Cultures from samples obtained from outpatients were excluded. A total of 1121 were included in the prevalence analysis, while 21 were excluded from this analysis since the samples were collected from sites and media other than those analyzed in the present study (blood, urine, respiratory tract, abdomen, rectum, skin/soft tissues, and vascular catheter). Moreover, for the sensitivity analysis 30 samples were excluded due to absence of results of meropenem susceptibility tests, resulting in 1112 samples for this specific analysis.

We estimated the prevalence and resistance rates of each bacteria and calculated the prevalence rates of carbapenem resistance at each site of infection and colonization.

Results

Across all sites and media analyzed, blood cultures had the lowest prevalence of the three GNB combined (12.55%). The site with the highest prevalence of all three GNB was the respiratory tract, where these bacteria represented almost half of all infections; of note, *Pseudomonas* spp. was identified in approximately one-third of all cultures from the respiratory tract (Graph 1). The three GNB also represented nearly a quarter of urine cultures and three-quarters of rectal swab cultures.


Table 1 – Prevalence of Gram-negative bacilli (GNB) by site of infection/colonization.

| Site of infection/colonization | Total | Acinetobacter spp. | Pseudomonas spp. | Klebsiella spp. | GNB |
|--------------------------------|-------|--------------------|------------------|-----------------|----------------|
| Blood culture ^a | 1339 | 1.79% (n=24) | 3.21% (n=43) | 7.54% (n=101) | 12.55% (n=168) |
| Respiratory tract ^a | 346 | 4.91% (n=17) | 30.92% (n=107) | 11.56% (n=40) | 47.4% (n=164) |
| Urine ^a | 784 | 1.15% (n=9) | 7.78% (n=61) | 15.18% (n=119) | 24.11% (n=189) |
| Abdomen ^a | 112 | 3.57% (n=4) | 5.36% (n=6) | 11.61% (n=13) | 20.54% (n=23) |
| Skin/soft tissues ^a | 313 | 1.92% (n=6) | 12.46% (n=39) | 8.31% (n=26) | 22.68% (n=71) |
| Vascular catheter ^a | 189 | 5.29% (n=10) | 6.88% (n=13) | 9.52% (n=18) | 21.69% (n=41) |
| Rectal swab ^b | 614 | 14.82% (n=91) | 6.84% (n=42) | 54.07% (n=332) | 75.73% (n=465) |
| Total | 3697 | 4.3% (n=161) | 8.4% (n=311) | 17.5% (n=649) | 30.3% (n=1121) |

Abbreviation: GNB: Gram-negative bacilli.

^a Site of infection.

^b Site of colonization.



Graph 1 – Approximate prevalence rates of Gram-negative bacilli (GNB) at the respiratory tract.


The prevalence of these bacteria at other sites was around 20% (Table 1).

With respect to resistance to carbapenem among the three pathogens, the rate was highest for *Acinetobacter* spp. (74.55%, n=123), followed by *Klebsiella* spp. (45.79%, n=299),

and *Pseudomonas* spp. (25.17%, n=74). According to overall susceptibility to meropenem among all three GNB, 53.06% (n=590) were sensitive, 2.34% (n=26) were intermediately resistant, and 44.6% (n=496) were resistant to this antibiotic (Graph 2).

Table 2 shows the rates of resistance to meropenem across all three bacteria analyzed according to infection and colonization sites/media. The highest resistance rate (61.51%) was observed in the colonization site (rectum) and mostly for *Klebsiella* spp. Resistance of *Acinetobacter* spp. to meropenem at various infection sites/media ranged from 36.36% (blood) to 82.35% (respiratory tract); resistance at the colonization site (rectum) was 86.81%. Resistance of *Pseudomonas* spp. to meropenem was high in the colonization site (71.43%), but relatively low in other sites/media, ranging from 13.16% in skin/soft tissues to 25.81% in blood. The rate of meropenem resistance among *Klebsiella* spp. in the colonization site was 53.31%, while at infection sites/media, resistance to this agent ranged from 19.23% (skin/soft tissues) to 55.56% (vascular catheter).

Regarding the three GNB analyzed, the prevalence of carbapenem (meropenem) resistance ranged from 4.2% at skin/soft tissues to 12.07% at the respiratory tract; at the colonization site (rectum), this rate was 46.56%. At sites of infection, carbapenem-resistant *Acinetobacter* spp. and *Klebsiella* spp. were more prevalent in vascular catheter cultures, while carbapenem-resistant *Pseudomonas* spp. was more



Graph 2 – Susceptibility profile of Gram-negative bacilli (GNB).

Table 2 – Susceptibility profile of Gram-negative bacilli (GNB) by site of infection/colonization.

| Site of infection/colonization | Sensitive | Intermediately resistant | Resistant | Total (n) |
|--------------------------------|-----------|--------------------------|-----------|-----------|
| Blood culture ^a | 51.95% | 2.6% | 45.45% | 154 |
| <i>Acinetobacter</i> spp. | 63.64% | 0% | 36.36% | 22 |
| <i>Pseudomonas</i> spp. | 64.52% | 9.68% | 25.81% | 31 |
| <i>Klebsiella</i> spp. | 45.54% | 0.99% | 53.47% | 101 |
| Respiratory tract ^a | 70.25% | 3.8% | 25.95% | 158 |
| <i>Acinetobacter</i> spp. | 17.65% | 0% | 82.35% | 17 |
| <i>Pseudomonas</i> spp. | 80.2% | 5.94% | 13.86% | 101 |
| <i>Klebsiella</i> spp. | 67.5% | 0% | 32.5% | 40 |
| Urine ^a | 68.48% | 3.8% | 27.72% | 184 |
| <i>Acinetobacter</i> spp. | 55.56% | 0% | 44.44% | 9 |
| <i>Pseudomonas</i> spp. | 71.43% | 8.93% | 19.64% | 56 |
| <i>Klebsiella</i> spp. | 68.07% | 1.68% | 30.25% | 119 |
| Abdomen ^a | 69.57% | 0% | 30.43% | 23 |
| <i>Acinetobacter</i> spp. | 50% | 0% | 50% | 4 |
| <i>Pseudomonas</i> spp. | 83.33% | 0% | 16.67% | 6 |
| <i>Klebsiella</i> spp. | 69.23% | 0% | 30.77% | 13 |
| Skin/soft tissues ^a | 78.57% | 2.86% | 18.57% | 70 |
| <i>Acinetobacter</i> spp. | 50% | 0% | 50% | 6 |
| <i>Pseudomonas</i> spp. | 84.21% | 2.63% | 13.16% | 38 |
| <i>Klebsiella</i> spp. | 76.92% | 3.85% | 19.23% | 26 |
| Vascular catheter ^a | 45% | 2.5% | 52.5% | 40 |
| <i>Acinetobacter</i> spp. | 20% | 0% | 80% | 10 |
| <i>Pseudomonas</i> spp. | 66.67% | 8.33% | 25% | 12 |
| <i>Klebsiella</i> spp. | 44.44% | 0% | 55.56% | 18 |
| Other ^a | 55.56% | 5.56% | 38.89% | 18 |
| <i>Acinetobacter</i> spp. | 16.67% | 0% | 83.33% | 6 |
| <i>Pseudomonas</i> spp. | 62.5% | 12.5% | 25% | 8 |
| <i>Klebsiella</i> spp. | 100% | 0% | 0% | 4 |
| Rectal swab ^b | 37.42% | 1.08% | 61.51% | 465 |
| <i>Acinetobacter</i> spp. | 13.19% | 0% | 86.81% | 91 |
| <i>Pseudomonas</i> spp. | 16.67% | 11.9% | 71.43% | 42 |
| <i>Klebsiella</i> spp. | 46.69% | 0% | 53.31% | 332 |

Abbreviation: GNB: Gram-negative bacilli.
^a Site of infection.
^b Site of colonization.

Table 3 – Prevalence of carbapenem-resistant Gram-negative bacilli (CR-GNB).

| Site of infection/colonization | <i>Acinetobacter</i> spp. | <i>Pseudomonas</i> spp. | <i>Klebsiella</i> spp. | Total |
|--------------------------------|---------------------------|-------------------------|------------------------|--------|
| Blood culture ^a | 0.65% | 0.82% | 4.03% | 5.5% |
| Respiratory tract ^a | 4.04% | 4.28% | 3.75% | 12.07% |
| Urine ^a | 0.51% | 1.52% | 4.59% | 6.62% |
| Abdomen ^a | 1.78% | 0.89% | 3.57% | 6.24% |
| Skin/soft tissues ^a | 0.96% | 1.64% | 1.6% | 4.2% |
| Vascular catheter ^a | 4.23% | 1.72% | 5.29% | 11.24% |
| Rectal swab ^b | 12.86% | 4.88% | 28.82% | 46.56% |

Abbreviation: CR-GNB: carbapenem-resistant Gram-negative bacilli.
^a Site of infection.
^b Site of colonization.

prevalent in cultures of samples obtained from the respiratory tract (Table 3).

Discussion

Acinetobacter spp., *Pseudomonas* spp., and *Klebsiella* spp. are frequently isolated in samples collected from patients, reflecting their importance as human pathogens. Rates of carbapenem resistance in the present study varied according to species

and infection site, and although the rates found were lower than those reported in other similar institutions, they are still concerning due to the scarcity of therapeutic options.

The bacteria with the highest rate of resistance to carbapenem were *Acinetobacter* spp. (74.55%) (Graph 2). *Acinetobacter* spp. (mainly *A. baumannii*) is usually resistant to multiple drugs, and rates of carbapenem resistance among these pathogens have been described at 98.1% in China (2013),¹³ 91% in Greece (2014),¹⁴ 95% in India (2015–2016),¹⁵ 75.5% in Latin American countries (2011),¹⁶ and 76.8–100% in

Brazil.^{17,18} The lower rates of *Acinetobacter* spp. resistance to carbapenem found in our study may indicate that infections by these pathogens are well managed at our institution.

The bacteria with the lowest but nevertheless concerning resistance rate in our study were *Pseudomonas* spp. (25.17%) (Graph 2). This frequency was lower than the rates reported in Latin America in general (38.4%), Guatemala (75.8%), Peru (62.5%), and Ecuador (55.6%) in 2011¹⁶ and in ICUs in India between 2015 and 2016 (56%),¹⁵ and was more aligned with rates found in Spain in 2013 (24.52%)¹⁹ and other countries such as Poland, Lithuania, Slovakia, Hungary, Croatia, Romania, Bulgaria, and Greece, where the frequency of carbapenem resistance ranges from 25% to 50%.²⁰

The rate of *Klebsiella* spp. Resistance to meropenem was 45.79% (Graph 2), which is similar to the rate described in Rio Grande do Sul in 2016 (52.6%)²¹ but higher than that reported in São Paulo in 2015 (35.5%).²² Additionally, this rate is lower than the one documented in Greece in 2014 (62.3%).²³ In bacteremias (blood cultures), *Klebsiella* spp. had a resistance rate of 53.47%, which is higher than the rates reported in Italy (15% in 2010 and 32.3% in 2014) and Greece (27.8% in 2005), but lower than the rate described in Greece in 2014 (62.3%).²⁰

Cultures of vascular catheter and blood had the highest rates of carbapenem resistance considering all three GNB combined (52.5% and 45.45%, respectively) (Table 2). Vascular catheters and blood are the most concerning infection sites for carbapenem-resistant GNB. The sites and media with GNB with highest sensitivity rates to meropenem were the skin/soft tissues (78.57%), respiratory tract (70.25%), abdomen (69.57%), and urinary tract (68.48%) (Table 2), indicating that meropenem is more effective at these sites.

All sites associated with hospital-related infections had a relatively small prevalence of meropenem-resistant GNB. The following are recommendations of antibiotics with activity against GNB, keeping in mind that bacteremias and skin/soft tissue and vascular catheter infections should also cover Gram-positive cocci, with methicillin-resistant *Staphylococcus aureus* (MRSA) generally being the most prevalent MDR bacteria at these sites.

The three GNB together accounted for 12.55% of all bacteria identified in blood cultures, and the rate of carbapenem resistance among these GNB was 5.4%. The most prevalent of all three GNB was *Klebsiella* spp.; these pathogen represented 7.54% of all bacteria causing bacteremia (Table 3), of which 53.47% were resistant to meropenem (Table 2). Thus, only 4.03% of the bacteremias at our institution in 2017 were caused by meropenem-resistant *Klebsiella* spp. (Table 3). Given this low prevalence of carbapenem resistance, antibiotics with a narrower antibacterial spectrum than meropenem (such as cefepime and piperacillin-tazobactam) are suitable for patients without sepsis and with GNB positive blood culture while bacteria identification and antibiogram are pending.²⁰ In patients with sepsis, meropenem is the right therapeutic choice, while antibiotics such as polymyxin B, aminoglycosides, ceftolozane-tazobactam and ceftazidime-avibactam should be reserved for meropenem-resistant GNB^{20,24-26} and only for targeted treatment, i.e., when sensitivity tests are available and demonstrate resistance to meropenem.

Cultures of samples obtained from the respiratory tract had a high prevalence of *Pseudomonas* spp. (31%) (Graph 1),

with only 13.86% resistant to meropenem (Table 2). *Klebsiella* spp. were the second most prevalent GNB in the respiratory tract (11.56%) (Table 1). When combined, the three GNB showing resistance to meropenem accounted for 12.07% of the cultures of samples obtained from the respiratory tract (Table 3). This suggests that meropenem can be used for empirical treatment, while polymyxin B, aminoglycosides, and ceftazidime-avibactam should be reserved for treatment of carbapenem-resistant GNB.

The three GNB surveyed accounted for 24.11% of all positive urine cultures, and the prevalence of carbapenem resistance among these GNB cultured from the urinary tract was 6.62% (Table 3). *Klebsiella* spp. were isolated from 15.18% of the urine cultures, which is roughly twice the prevalence of *Pseudomonas* spp. in these cultures, the second of all three GNB surveyed (Table 1). Aminoglycosides, ceftazidime, cefepime, or piperacillin-tazobactam²⁰ are all suitable antibiotics in most cases of urinary tract infection caused by these three GNB.

Among intra-abdominal infections, *Klebsiella* spp. were the most frequent pathogens identified (11.1% of the total) (Table 1) and were resistant to meropenem in 30.77% of the cases (Table 2). The prevalence of carbapenem-resistant GNB in intra-abdominal samples was only 6.24% (Table 3). Among alternatives for intra-abdominal infections, cefepime combined with metronidazole or piperacillin-tazobactam²⁰ are good options, while meropenem should be reserved for patients with sepsis.

The three GNB analyzed represented 22.68% of the total samples obtained from skin/soft tissues (Table 1); among these, only 4.2% were resistant to carbapenem (Table 3). Cefepime or piperacillin-tazobactam²⁰ are more suitable antibiotics for empirical treatment. Polymyxin B, aminoglycosides, and ceftazidime-avibactam are probably the best choices for targeted treatment of carbapenem-resistant GNB.

Gram-positive cocci predominated in vascular catheter infections. In all, 11.24% of all positive vascular catheter cultures were caused by a combination of the three GNB showing carbapenem resistance (Table 3). This finding reinforces the use of antibiotics reserved for carbapenem resistance only when resistance is confirmed by susceptibility testing.

Among positive cultures of rectal swab – which represent colonization rather than infection – the combined rates of carbapenem resistance among the three GNB analyzed was 46.56% (Table 3). Among these, *Klebsiella* spp. was isolated from 54.07% of the cases (Table 1), of which just over half (53.31%) were resistant to meropenem (Table 2). This high prevalence of rectal swab samples from patients colonized by carbapenem-resistant GNB shows the importance of infection control measures at the hospital level to prevent the spread of these bacteria as a potential cause of health care-related infections.

Conclusions

Considering the complexity of the patients seen at the CHC-UFPR, the rates of carbapenem-resistant GNB were relatively low when compared to national and international rates. This probably indicates that the infection control measures taken at the hospital are currently effective, but should not forego

the adoption of more strict contact precautions measures (mainly due to the high prevalence of patients colonized by carbapenem-resistant GNB) and the use of alternative antibiotic therapies to spare carbapenems whenever possible. Meropenem remains a good empirical therapeutic option to treat patients with severe hospital-acquired infection (sepsis) at CHC-UFPR. The correct use of antibiotics is essential to avoid the consequences of inadequate treatment, such as increased mortality and hospital costs, along with the dissemination of MDR bacteria.

Conflicts of interest

The authors declare no conflicts of interest.

REFERENCES

1. von Wintersdorff CJH, Penders J, van Niekerk JM. Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. *Front Microbiol.* 2016;7, <http://dx.doi.org/10.3389/fmicb.2016.01673>.
2. Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN. Non-prescription antimicrobial use worldwide: a systematic review. *Lancet Infect Dis.* 2011;11:692-701, [http://dx.doi.org/10.1016/S1473-3099\(11\)70054-8](http://dx.doi.org/10.1016/S1473-3099(11)70054-8). Non-prescription.
3. Woolhouse M, Ward M, Bunnik B, Van Farrar J, Ward M, Woolhouse M. Antimicrobial resistance in humans, livestock and wider environment. *R Soc Publ.* 2015;370, <http://dx.doi.org/10.1098/rstb.2014.0083>.
4. Ponce De León-Rosales S, Arredondo-Hernández R, López-Vidal Y. Resistance to antibiotic: a serious global problem. *Gac Med Mex.* 2015;151:632-9.
5. Laxminarayan R, Mouton RP, Pant S, et al. Access to effective antimicrobials: a worldwide challenge. *Lancet.* 2016;387:168-75, [http://dx.doi.org/10.1016/S0140-6736\(15\)00474-2](http://dx.doi.org/10.1016/S0140-6736(15)00474-2).
6. World Health Organization. Global action plan on antimicrobial resistance. Geneva: World Health Organization; 2015. p. 1-28, 978 92 4 150976 3.
7. Codjoe F, Donkor E. Carbapenem resistance: a review. *Med Sci.* 2018;6:1, <http://dx.doi.org/10.3390/medsci6010001>.
8. Al-Zahrani IA. Routine detection of carbapenem-resistant gram-negative bacilli in clinical laboratories. A review of current challenge. *Saudi Med J.* 2018;39:861-72, <http://dx.doi.org/10.15537/smj.2018.9.22840>.
9. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESCAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis.* 2009;02111:1-12, <http://dx.doi.org/10.1086/595011>.
10. Ruppé É, Woerther PL, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. *Ann Intensive Care.* 2015;5, <http://dx.doi.org/10.1186/s13613-015-0061-0>.
11. Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. *Lancet Infect Dis.* 2014;14:742-50, [http://dx.doi.org/10.1016/S1473-3099\(14\)70780-7](http://dx.doi.org/10.1016/S1473-3099(14)70780-7).
12. IBGE. Estimativas da população residente no Brasil e unidades da federação com data de referência em 1° de julho de 2018. *Dir Pesqui - DPE - Coord Popul e Indicadores Sociais - COPIS;* 2018.
13. Jiang M, Liu L, Ma Y, Zhang Z, Li N, Zhang F. Molecular epidemiology of multi-drug resistant *Acinetobacter baumannii* isolated in Shandong. *Front Microbiol.* 2016;7:1-9, <http://dx.doi.org/10.3389/fmicb.2016.01687>.
14. Oikonomou O, Sarrou S, Papagiannitsis CC, Georgiadou S, Mantzaris K, Zakyntinos E. Rapid dissemination of colistin and carbapenem resistant *Acinetobacter baumannii* in Central Greece: mechanisms of resistance, molecular identification and epidemiological data. *BMC Infect Dis.* 2015;13-8, <http://dx.doi.org/10.1186/s12879-015-1297-x>.
15. Agarwal S, Kakati B, Khanduri S, Gupta S. Emergence of carbapenem resistant non-fermenting Gram-negative bacilli isolated in an ICU of a tertiary care hospital. *J Clin Diagnostic Res.* 2017;11:12-5, <http://dx.doi.org/10.7860/JCDR/2017/24023.9317>.
16. Jones RN, Guzman-Blanco M, Gales AC, et al. Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). *Brazilian J Infect Dis.* 2013;17:672-81, <http://dx.doi.org/10.1016/j.bjid.2013.07.002>.
17. Castilho SRA, Godoy DM, Guilarde AO, et al. *Acinetobacter baumannii* strains isolated from patients in intensive care units in Goiânia Brazil: Molecular and drug susceptibility profiles; 2017. p. 1-13.
18. Cortivo GD, Gutberlet A, Ferreira JA. Antimicrobial resistance profiles and oxacillinase genes in carbapenem-resistant *Acinetobacter baumannii* isolated from hospitalized patients in Santa Catarina, Brazil. *Rev Soc Bras Med Trop.* 2015;48:699-705.
19. Garcinuño P, Santibañez M, Gimeno L, et al. Empirical monotherapy with meropenem or combination therapy: the microbiological point of view. *Eur J Clin Microbiol Infect Dis.* 2016;35:1851-5.
20. Hawkey PM, Warren RE, Livermore DM, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. *J Antimicrob Chemother.* 2018;73, <http://dx.doi.org/10.1093/jac/dky027>.
21. Lorenzoni VV, Rubert C, Rampelotto RF, Hörner R. Increased antimicrobial resistance in *Klebsiella pneumoniae* from a University Hospital in Rio Grande do Sul, Brazil. *Rev Soc Bras Med Trop.* 2018;51:676-9, <http://dx.doi.org/10.1590/0037-8682-0362-2017>.
22. Bartolleti F, Silva Seco B, Capuzzo dos Santos C, et al. Polymyxin B resistance in carbapenem-resistant *Klebsiella pneumoniae*, São Paulo, Brazil. *Emerg Infect Dis.* 2016;22:1849-51.
23. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant *Enterobacteriaceae*: the impact and evolution of a global menace. *J Infect Dis.* 2017;215:1-9, <http://dx.doi.org/10.1093/infdis/jiw282>.
24. Soriano A, Llinares P, Marco F, Cantón R, González J, Maseda E. Antibiotic selection in the treatment of acute invasive infections by *Pseudomonas aeruginosa*: Guidelines by the Spanish Society of Chemotherapy. *Rev Esp Quimioter.* 2018;31:78-100.
25. Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK. Antimicrobial activity of ceftazidime-resistant *Enterobacteriaceae* and *Pseudomonas aeruginosa* isolates from U.S. Medical Centers, 2013 to 2016. *Antimicrob Agents Chemother.* 2017;61:1-11, <http://dx.doi.org/10.1128/AAC.01045-1>.
26. Van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β -lactam/ β -lactamase inhibitor combinations. *Clin Infect Dis.* 2016;63:234-41, <http://dx.doi.org/10.1093/cid/ciw243>.